• LAST PRICE
    0.7236
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.7243/ 25
  • Ask / Lots
    0.7289/ 1
  • Open / Previous Close
    0.0000 / 0.7236
  • Day Range
    ---
  • 52 Week Range
    Low 0.6700
    High 5.9500
  • Volume
    4,134
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.7005
TimeVolumeSPRB
09:32 ET124740.7001
09:34 ET3000.7069
09:36 ET11790.701
09:45 ET8000.696263
09:54 ET20000.6998
09:56 ET41640.7
09:57 ET1000.7064
10:01 ET30370.7099
10:03 ET3000.7098
10:06 ET1000.7098
10:08 ET5000.7032
10:12 ET34460.7098
10:14 ET36490.7124
10:15 ET5000.7149
10:24 ET11120.7144
10:26 ET9850.7149
10:28 ET60870.7187
10:30 ET15500.718
10:35 ET1000.7199
10:37 ET1000.7199
10:39 ET145040.7187
10:42 ET1000.71445
10:46 ET1000.7145
10:48 ET77330.7144
10:51 ET11680.7101
10:57 ET13540.7102
11:00 ET1000.7102
11:04 ET1000.7142
11:09 ET4000.7142
11:13 ET1000.7142
11:15 ET4000.7141
11:18 ET2000.7198
11:22 ET10000.7188
11:24 ET63040.72
11:26 ET52000.720201
11:33 ET3750.7202
11:38 ET80140.7137
11:40 ET10000.7151
11:44 ET8000.7203
11:49 ET1000.72
11:54 ET3000.722
11:56 ET1000.7219
11:58 ET12000.7151
12:16 ET122880.7152
12:18 ET125140.7218
12:20 ET19160.7249
12:21 ET1000.7249
12:30 ET38880.7225
12:32 ET2000.7248
12:48 ET2000.7248
12:57 ET62400.7201
12:59 ET4000.7152
01:01 ET6040.7245
01:12 ET7000.7157
01:14 ET2000.7198
01:21 ET1000.7198
01:28 ET1000.7196
01:30 ET1000.7196
01:32 ET5850.7179
01:33 ET1000.7199
01:35 ET20000.7242
01:37 ET7000.7222
01:57 ET37000.7242
02:00 ET3000.7235
02:02 ET7000.7236
02:08 ET16470.7247
02:15 ET6000.7246
02:18 ET1000.7247
02:20 ET2000.72375
02:24 ET7090.7241
02:26 ET1000.7241
02:31 ET1000.7241
02:40 ET61790.7237
02:42 ET10370.72405
02:44 ET1000.72405
02:45 ET91000.72439
02:47 ET38160.7299
02:49 ET2000.7299
02:51 ET1000.72855
02:54 ET1000.72855
02:56 ET2000.7286
02:58 ET2000.7299
03:02 ET12430.7286
03:03 ET2000.7314
03:07 ET23000.7327
03:12 ET48310.7327
03:14 ET16030.73275
03:16 ET18920.7353
03:18 ET4000.7366
03:20 ET38200.7353
03:21 ET8300.7366
03:23 ET6030.7366
03:25 ET37780.735
03:27 ET9000.7329
03:34 ET10000.7332
03:38 ET1000.733
03:41 ET3460.734
03:43 ET6000.7348
03:48 ET1000.733
03:50 ET22000.733
03:52 ET2000.733
03:54 ET10000.7301
03:56 ET749810.72785
03:57 ET19090.723
03:59 ET17130.7236
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSPRB
Spruce Biosciences Inc
29.8M
-0.6x
---
United StatesAWH
Aspira Women's Health Inc
26.8M
-1.6x
---
United StatesJAGX
Jaguar Health Inc
21.0M
-0.1x
---
United StatesBOLT
Bolt Biotherapeutics Inc
28.9M
-0.5x
---
United StatesCIPI
Correlate Energy Corp
28.7M
-1.9x
---
United StatesVBIV
VBI Vaccines Inc
17.2M
-0.1x
---
As of 2024-05-31

Company Information

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Contact Information

Headquarters
611 Gateway Boulevard, Suite 740SOUTH SAN FRANCISCO, CA, United States 94080
Phone
415-655-4168
Fax
302-636-5454

Executives

Executive Chairman of the Board
Michael Grey
President, Chief Financial Officer
Samir Gharib
Chief Executive Officer, Director
Javier Szwarcberg
Chief Medical Officer
Ralph Charlton
Independent Director
Tiba Aynechi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$29.8M
Revenue (TTM)
$10.1M
Shares Outstanding
41.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.49
EPS
$-1.15
Book Value
$1.86
P/E Ratio
-0.6x
Price/Sales (TTM)
2.9
Price/Cash Flow (TTM)
---
Operating Margin
-507.82%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.